The Experts below are selected from a list of 282 Experts worldwide ranked by ideXlab platform
M Moreno - One of the best experts on this subject based on the ideXlab platform.
-
SAT0295 ANTI-Ro52/TRIM21 antibodies are associated with QT interval pRolongation in patients with systemic lupus erythematosus
Annals of the Rheumatic Diseases, 2017Co-Authors: Lf Perez, Lh Silveira, L Amezcua, O Estevez, M MorenoAbstract:BackgRound Long QT syndRome (LQTS) is characterized by an abnormal QT corrected (QTc) interval pRolongation that is associated with increased risk of sudden death. Studies have associated LQTS with several rheumatic conditions, and evidence points towards a link between the degree of systemic inflammation and the duration of QTc interval. Moreover, recent evidence suggests that anti-Ro antibodies may play a Role in the QTc pRolongation by mechanisms not fully understood, thus constituting a novel autoimmune-mediated LQTS. Objectives This study was aimed to assess whether QTc interval pRolongation is associated with the presence of anti-Ro antibodies in SLE, particularly with reactivities against Ro52/TRIM21 antigens. Methods Consecutive patients fulfilling the 1997 ACR criteria for SLE were included. Patients with history of ischemic heart disease, with implantable pacemakers, and those taking drugs that potentially could affect QT interval (except for antimalarials) were excluded. Patients underwent a resting 12-lead electRocardiogram recording to measure QT interval corrected by BazzetOs formula. A QTc interval duration greater than 460 msec in women and 440 msec in men was set to be abnormal. Serum anti-Ro and anti-Ro52/TRIM21 Antibody levels were measured by ELISA. Data were expressed as frequencies and means (± standard deviation), and differences were tested by YatesO continuity corrected chi square or Mann-Whitney tests, while linear regressions were performed to assess linearity between autoAntibody levels and QTc duration. The GraphPad Prism 4.02 software was used for calculations. Results Sixty-six patients with mean age of 39±13 years (57 female gender) were included. A QTc pRolongation was found in 10 patients (15%), with mean QTc interval of 470±18 msec as compared to 414±23 msec in those with no LQTS. Main clinical and demographic characteristics were similar for both gRoups, except for a lesser use of antimalarials and higher serum creatinine levels in patients with LQTS. Disease activity was similar between gRoups.Anti-Ro Antibody levels were significantly higher in patients with pRolonged QT interval (75±66 U/mL versus 29±44 U/mL; P=0.005); similarly, anti-Ro52/TRIM21 levels were higher in those with LQTS (50±55 U/mL versus 14±30 U/mL; P=0.01). Notably, a linear association (see the Figure) between the QTc intervals and levels of anti-Ro antibodies (r2=0.073; P=0.02) and anti-Ro52/TRIM21antibodies (r2=0.078; P=0.02) was observed. Conclusions Our results strengthen the hypothesis that a specific autoAntibody-mediated LQTS occur in SLE patients positive to anti-Ro antibodies. This interference in the ventricular repolarization appears to be associated with increased levels of antibodies against Ro52/TRIM21 antigens, and supports the realization of an electRocardiogram as part of the Routinely evaluation in SLE patient with circulating anti-Ro antibodies. Disclosure of Interest None declared
-
SAT0295 ANTI-Ro52/TRIM21 antibodies are associated with QT interval pRolongation in patients with systemic lupus erythematosus
Poster Presentations, 2017Co-Authors: Lf Perez, Lh Silveira, L Amezcua, O Estevez, M MorenoAbstract:BackgRound Long QT syndRome (LQTS) is characterized by an abnormal QT corrected (QTc) interval pRolongation that is associated with increased risk of sudden death. Studies have associated LQTS with several rheumatic conditions, and evidence points towards a link between the degree of systemic inflammation and the duration of QTc interval. Moreover, recent evidence suggests that anti-Ro antibodies may play a Role in the QTc pRolongation by mechanisms not fully understood, thus constituting a novel autoimmune-mediated LQTS. Objectives This study was aimed to assess whether QTc interval pRolongation is associated with the presence of anti-Ro antibodies in SLE, particularly with reactivities against Ro52/TRIM21 antigens. Methods Consecutive patients fulfilling the 1997 ACR criteria for SLE were included. Patients with history of ischemic heart disease, with implantable pacemakers, and those taking drugs that potentially could affect QT interval (except for antimalarials) were excluded. Patients underwent a resting 12-lead electRocardiogram recording to measure QT interval corrected by BazzetOs formula. A QTc interval duration greater than 460 msec in women and 440 msec in men was set to be abnormal. Serum anti-Ro and anti-Ro52/TRIM21 Antibody levels were measured by ELISA. Data were expressed as frequencies and means (± standard deviation), and differences were tested by YatesO continuity corrected chi square or Mann-Whitney tests, while linear regressions were performed to assess linearity between autoAntibody levels and QTc duration. The GraphPad Prism 4.02 software was used for calculations. Results Sixty-six patients with mean age of 39±13 years (57 female gender) were included. A QTc pRolongation was found in 10 patients (15%), with mean QTc interval of 470±18 msec as compared to 414±23 msec in those with no LQTS. Main clinical and demographic characteristics were similar for both gRoups, except for a lesser use of antimalarials and higher serum creatinine levels in patients with LQTS. Disease activity was similar between gRoups.Anti-Ro Antibody levels were significantly higher in patients with pRolonged QT interval (75±66 U/mL versus 29±44 U/mL; P=0.005); similarly, anti-Ro52/TRIM21 levels were higher in those with LQTS (50±55 U/mL versus 14±30 U/mL; P=0.01). Notably, a linear association (see the Figure) between the QTc intervals and levels of anti-Ro antibodies (r2=0.073; P=0.02) and anti-Ro52/TRIM21antibodies (r2=0.078; P=0.02) was observed. Conclusions Our results strengthen the hypothesis that a specific autoAntibody-mediated LQTS occur in SLE patients positive to anti-Ro antibodies. This interference in the ventricular repolarization appears to be associated with increased levels of antibodies against Ro52/TRIM21 antigens, and supports the realization of an electRocardiogram as part of the Routinely evaluation in SLE patient with circulating anti-Ro antibodies. Disclosure of Interest None declared
-
sat0295 anti Ro52 trim21 antibodies are associated with qt interval pRolongation in patients with systemic lupus erythematosus
Annals of the Rheumatic Diseases, 2017Co-Authors: Lf Perez, Lh Silveira, L Amezcua, O Estevez, M MorenoAbstract:BackgRound Long QT syndRome (LQTS) is characterized by an abnormal QT corrected (QTc) interval pRolongation that is associated with increased risk of sudden death. Studies have associated LQTS with several rheumatic conditions, and evidence points towards a link between the degree of systemic inflammation and the duration of QTc interval. Moreover, recent evidence suggests that anti-Ro antibodies may play a Role in the QTc pRolongation by mechanisms not fully understood, thus constituting a novel autoimmune-mediated LQTS. Objectives This study was aimed to assess whether QTc interval pRolongation is associated with the presence of anti-Ro antibodies in SLE, particularly with reactivities against Ro52/TRIM21 antigens. Methods Consecutive patients fulfilling the 1997 ACR criteria for SLE were included. Patients with history of ischemic heart disease, with implantable pacemakers, and those taking drugs that potentially could affect QT interval (except for antimalarials) were excluded. Patients underwent a resting 12-lead electRocardiogram recording to measure QT interval corrected by BazzetOs formula. A QTc interval duration greater than 460 msec in women and 440 msec in men was set to be abnormal. Serum anti-Ro and anti-Ro52/TRIM21 Antibody levels were measured by ELISA. Data were expressed as frequencies and means (± standard deviation), and differences were tested by YatesO continuity corrected chi square or Mann-Whitney tests, while linear regressions were performed to assess linearity between autoAntibody levels and QTc duration. The GraphPad Prism 4.02 software was used for calculations. Results Sixty-six patients with mean age of 39±13 years (57 female gender) were included. A QTc pRolongation was found in 10 patients (15%), with mean QTc interval of 470±18 msec as compared to 414±23 msec in those with no LQTS. Main clinical and demographic characteristics were similar for both gRoups, except for a lesser use of antimalarials and higher serum creatinine levels in patients with LQTS. Disease activity was similar between gRoups.Anti-Ro Antibody levels were significantly higher in patients with pRolonged QT interval (75±66 U/mL versus 29±44 U/mL; P=0.005); similarly, anti-Ro52/TRIM21 levels were higher in those with LQTS (50±55 U/mL versus 14±30 U/mL; P=0.01). Notably, a linear association (see the Figure) between the QTc intervals and levels of anti-Ro antibodies (r2=0.073; P=0.02) and anti-Ro52/TRIM21antibodies (r2=0.078; P=0.02) was observed. Conclusions Our results strengthen the hypothesis that a specific autoAntibody-mediated LQTS occur in SLE patients positive to anti-Ro antibodies. This interference in the ventricular repolarization appears to be associated with increased levels of antibodies against Ro52/TRIM21 antigens, and supports the realization of an electRocardiogram as part of the Routinely evaluation in SLE patient with circulating anti-Ro antibodies. Disclosure of Interest None declared
Richard D. Sontheimer - One of the best experts on this subject based on the ideXlab platform.
-
Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus
Current opinion in rheumatology, 1997Co-Authors: Victoria P. Werth, Jan P. Dutz, Richard D. SontheimerAbstract:The mechanisms of cutaneous lupus erythematosus are under active investigation, and important advances have been made. Humoral mechanisms are likely important in subacute cutaneous lupus erythematosus, the cutaneous subset most associated with the Ro Antibody. Many advances have been made in understanding the various Ro epitopes and the specificities of the Ro Antibody response. Lupus mice experiments have pRovided insight into the contributing Roles of various T-cell subsets. Variations in cytokine pRoduction related to genetic polymorphisms and induction by ultraviolet light combined with alterations in selectins and adhesion molecules contribute to the accumulation of inflammatory cells in cutaneous lupus erythematosus. It is important to institute aggressive systemic therapy when there is widespread scarring disease. Antimalarial agents continue to be first-line systemic drugs, and our understanding of the use of combination antimalarial agents and pRoper dosing limits pRoblems with toxicity and impRoves efficacy. Other therapies, including thalidomide, are helpful for patients with resistant disease.
Lf Perez - One of the best experts on this subject based on the ideXlab platform.
-
SAT0295 ANTI-Ro52/TRIM21 antibodies are associated with QT interval pRolongation in patients with systemic lupus erythematosus
Annals of the Rheumatic Diseases, 2017Co-Authors: Lf Perez, Lh Silveira, L Amezcua, O Estevez, M MorenoAbstract:BackgRound Long QT syndRome (LQTS) is characterized by an abnormal QT corrected (QTc) interval pRolongation that is associated with increased risk of sudden death. Studies have associated LQTS with several rheumatic conditions, and evidence points towards a link between the degree of systemic inflammation and the duration of QTc interval. Moreover, recent evidence suggests that anti-Ro antibodies may play a Role in the QTc pRolongation by mechanisms not fully understood, thus constituting a novel autoimmune-mediated LQTS. Objectives This study was aimed to assess whether QTc interval pRolongation is associated with the presence of anti-Ro antibodies in SLE, particularly with reactivities against Ro52/TRIM21 antigens. Methods Consecutive patients fulfilling the 1997 ACR criteria for SLE were included. Patients with history of ischemic heart disease, with implantable pacemakers, and those taking drugs that potentially could affect QT interval (except for antimalarials) were excluded. Patients underwent a resting 12-lead electRocardiogram recording to measure QT interval corrected by BazzetOs formula. A QTc interval duration greater than 460 msec in women and 440 msec in men was set to be abnormal. Serum anti-Ro and anti-Ro52/TRIM21 Antibody levels were measured by ELISA. Data were expressed as frequencies and means (± standard deviation), and differences were tested by YatesO continuity corrected chi square or Mann-Whitney tests, while linear regressions were performed to assess linearity between autoAntibody levels and QTc duration. The GraphPad Prism 4.02 software was used for calculations. Results Sixty-six patients with mean age of 39±13 years (57 female gender) were included. A QTc pRolongation was found in 10 patients (15%), with mean QTc interval of 470±18 msec as compared to 414±23 msec in those with no LQTS. Main clinical and demographic characteristics were similar for both gRoups, except for a lesser use of antimalarials and higher serum creatinine levels in patients with LQTS. Disease activity was similar between gRoups.Anti-Ro Antibody levels were significantly higher in patients with pRolonged QT interval (75±66 U/mL versus 29±44 U/mL; P=0.005); similarly, anti-Ro52/TRIM21 levels were higher in those with LQTS (50±55 U/mL versus 14±30 U/mL; P=0.01). Notably, a linear association (see the Figure) between the QTc intervals and levels of anti-Ro antibodies (r2=0.073; P=0.02) and anti-Ro52/TRIM21antibodies (r2=0.078; P=0.02) was observed. Conclusions Our results strengthen the hypothesis that a specific autoAntibody-mediated LQTS occur in SLE patients positive to anti-Ro antibodies. This interference in the ventricular repolarization appears to be associated with increased levels of antibodies against Ro52/TRIM21 antigens, and supports the realization of an electRocardiogram as part of the Routinely evaluation in SLE patient with circulating anti-Ro antibodies. Disclosure of Interest None declared
-
SAT0295 ANTI-Ro52/TRIM21 antibodies are associated with QT interval pRolongation in patients with systemic lupus erythematosus
Poster Presentations, 2017Co-Authors: Lf Perez, Lh Silveira, L Amezcua, O Estevez, M MorenoAbstract:BackgRound Long QT syndRome (LQTS) is characterized by an abnormal QT corrected (QTc) interval pRolongation that is associated with increased risk of sudden death. Studies have associated LQTS with several rheumatic conditions, and evidence points towards a link between the degree of systemic inflammation and the duration of QTc interval. Moreover, recent evidence suggests that anti-Ro antibodies may play a Role in the QTc pRolongation by mechanisms not fully understood, thus constituting a novel autoimmune-mediated LQTS. Objectives This study was aimed to assess whether QTc interval pRolongation is associated with the presence of anti-Ro antibodies in SLE, particularly with reactivities against Ro52/TRIM21 antigens. Methods Consecutive patients fulfilling the 1997 ACR criteria for SLE were included. Patients with history of ischemic heart disease, with implantable pacemakers, and those taking drugs that potentially could affect QT interval (except for antimalarials) were excluded. Patients underwent a resting 12-lead electRocardiogram recording to measure QT interval corrected by BazzetOs formula. A QTc interval duration greater than 460 msec in women and 440 msec in men was set to be abnormal. Serum anti-Ro and anti-Ro52/TRIM21 Antibody levels were measured by ELISA. Data were expressed as frequencies and means (± standard deviation), and differences were tested by YatesO continuity corrected chi square or Mann-Whitney tests, while linear regressions were performed to assess linearity between autoAntibody levels and QTc duration. The GraphPad Prism 4.02 software was used for calculations. Results Sixty-six patients with mean age of 39±13 years (57 female gender) were included. A QTc pRolongation was found in 10 patients (15%), with mean QTc interval of 470±18 msec as compared to 414±23 msec in those with no LQTS. Main clinical and demographic characteristics were similar for both gRoups, except for a lesser use of antimalarials and higher serum creatinine levels in patients with LQTS. Disease activity was similar between gRoups.Anti-Ro Antibody levels were significantly higher in patients with pRolonged QT interval (75±66 U/mL versus 29±44 U/mL; P=0.005); similarly, anti-Ro52/TRIM21 levels were higher in those with LQTS (50±55 U/mL versus 14±30 U/mL; P=0.01). Notably, a linear association (see the Figure) between the QTc intervals and levels of anti-Ro antibodies (r2=0.073; P=0.02) and anti-Ro52/TRIM21antibodies (r2=0.078; P=0.02) was observed. Conclusions Our results strengthen the hypothesis that a specific autoAntibody-mediated LQTS occur in SLE patients positive to anti-Ro antibodies. This interference in the ventricular repolarization appears to be associated with increased levels of antibodies against Ro52/TRIM21 antigens, and supports the realization of an electRocardiogram as part of the Routinely evaluation in SLE patient with circulating anti-Ro antibodies. Disclosure of Interest None declared
-
sat0295 anti Ro52 trim21 antibodies are associated with qt interval pRolongation in patients with systemic lupus erythematosus
Annals of the Rheumatic Diseases, 2017Co-Authors: Lf Perez, Lh Silveira, L Amezcua, O Estevez, M MorenoAbstract:BackgRound Long QT syndRome (LQTS) is characterized by an abnormal QT corrected (QTc) interval pRolongation that is associated with increased risk of sudden death. Studies have associated LQTS with several rheumatic conditions, and evidence points towards a link between the degree of systemic inflammation and the duration of QTc interval. Moreover, recent evidence suggests that anti-Ro antibodies may play a Role in the QTc pRolongation by mechanisms not fully understood, thus constituting a novel autoimmune-mediated LQTS. Objectives This study was aimed to assess whether QTc interval pRolongation is associated with the presence of anti-Ro antibodies in SLE, particularly with reactivities against Ro52/TRIM21 antigens. Methods Consecutive patients fulfilling the 1997 ACR criteria for SLE were included. Patients with history of ischemic heart disease, with implantable pacemakers, and those taking drugs that potentially could affect QT interval (except for antimalarials) were excluded. Patients underwent a resting 12-lead electRocardiogram recording to measure QT interval corrected by BazzetOs formula. A QTc interval duration greater than 460 msec in women and 440 msec in men was set to be abnormal. Serum anti-Ro and anti-Ro52/TRIM21 Antibody levels were measured by ELISA. Data were expressed as frequencies and means (± standard deviation), and differences were tested by YatesO continuity corrected chi square or Mann-Whitney tests, while linear regressions were performed to assess linearity between autoAntibody levels and QTc duration. The GraphPad Prism 4.02 software was used for calculations. Results Sixty-six patients with mean age of 39±13 years (57 female gender) were included. A QTc pRolongation was found in 10 patients (15%), with mean QTc interval of 470±18 msec as compared to 414±23 msec in those with no LQTS. Main clinical and demographic characteristics were similar for both gRoups, except for a lesser use of antimalarials and higher serum creatinine levels in patients with LQTS. Disease activity was similar between gRoups.Anti-Ro Antibody levels were significantly higher in patients with pRolonged QT interval (75±66 U/mL versus 29±44 U/mL; P=0.005); similarly, anti-Ro52/TRIM21 levels were higher in those with LQTS (50±55 U/mL versus 14±30 U/mL; P=0.01). Notably, a linear association (see the Figure) between the QTc intervals and levels of anti-Ro antibodies (r2=0.073; P=0.02) and anti-Ro52/TRIM21antibodies (r2=0.078; P=0.02) was observed. Conclusions Our results strengthen the hypothesis that a specific autoAntibody-mediated LQTS occur in SLE patients positive to anti-Ro antibodies. This interference in the ventricular repolarization appears to be associated with increased levels of antibodies against Ro52/TRIM21 antigens, and supports the realization of an electRocardiogram as part of the Routinely evaluation in SLE patient with circulating anti-Ro antibodies. Disclosure of Interest None declared
Te-yu Lin - One of the best experts on this subject based on the ideXlab platform.
-
Positive Anti-SSA/Ro Antibody in a Woman with SARS-CoV-2 Infection Using Immunophenotyping: A Case Report
Medicina (Kaunas Lithuania), 2020Co-Authors: Po-i Huang, Ting-chun Lin, Feng-cheng Liu, Te-yu LinAbstract:The clinical spectrum of novel coRonavirus infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia, with respiratory failure and even death. Autoantibodies, especially antiphospholipid antibodies, can occur in severe infections. Other autoantibodies are seldom reported. Here, a 60-year-old female patient without dry-mouth symptoms detected positive for anti-60 kDa SSA/Ro antibodies on day 43 after severe acute respiratory syndRome coRonavirus 2 (SARS-CoV-2) infection. To investigate this unique clinical case of SARS-CoV-2 infection, immunological characteristics of this case were detected by using flow cytometry and were compared to the other three gRoups of patients-health subjects, 2019 novel coRonavirus disease (COVID-19) recovery patients, and Sjogren's syndRome (SS) patients. Monitoring the autoAntibody level and the development of subsequently related autoimmune diseases are warranted after SARS-CoV-2 infection.
-
positive anti ssa Ro Antibody in a woman with sars cov 2 infection using immunophenotyping a case report
Medicina-buenos Aires, 2020Co-Authors: Po-i Huang, Ting-chun Lin, Feng-cheng Liu, Te-yu LinAbstract:The clinical spectrum of novel coRonavirus infection appears to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia, with respiratory failure and even death. Autoantibodies, especially antiphospholipid antibodies, can occur in severe infections. Other autoantibodies are seldom reported. Here, a 60-year-old female patient without dry-mouth symptoms detected positive for anti-60 kDa SSA/Ro antibodies on day 43 after severe acute respiratory syndRome coRonavirus 2 (SARS-CoV-2) infection. To investigate this unique clinical case of SARS-CoV-2 infection, immunological characteristics of this case were detected by using flow cytometry and were compared to the other three gRoups of patients-health subjects, 2019 novel coRonavirus disease (COVID-19) recovery patients, and Sjogren's syndRome (SS) patients. Monitoring the autoAntibody level and the development of subsequently related autoimmune diseases are warranted after SARS-CoV-2 infection.
Victoria P. Werth - One of the best experts on this subject based on the ideXlab platform.
-
Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus
Current opinion in rheumatology, 1997Co-Authors: Victoria P. Werth, Jan P. Dutz, Richard D. SontheimerAbstract:The mechanisms of cutaneous lupus erythematosus are under active investigation, and important advances have been made. Humoral mechanisms are likely important in subacute cutaneous lupus erythematosus, the cutaneous subset most associated with the Ro Antibody. Many advances have been made in understanding the various Ro epitopes and the specificities of the Ro Antibody response. Lupus mice experiments have pRovided insight into the contributing Roles of various T-cell subsets. Variations in cytokine pRoduction related to genetic polymorphisms and induction by ultraviolet light combined with alterations in selectins and adhesion molecules contribute to the accumulation of inflammatory cells in cutaneous lupus erythematosus. It is important to institute aggressive systemic therapy when there is widespread scarring disease. Antimalarial agents continue to be first-line systemic drugs, and our understanding of the use of combination antimalarial agents and pRoper dosing limits pRoblems with toxicity and impRoves efficacy. Other therapies, including thalidomide, are helpful for patients with resistant disease.
